Kidney Paired Donation

Paragonix Technologies Announces Global Registry for Pediatric Donor Heart Preservation; Enrolls First Patient

Retrieved on: 
Wednesday, July 28, 2021

Paragonix Technologies, Inc. today announces that the University of Florida Health (UF Health) is the first to enroll a pediatric heart transplant recipient into the Companys post-market registry, the Global Utilization And Registry Database for Improved preservAtion of donor HEARTs (GUARDIAN-HEART) Pediatric Registry.

Key Points: 
  • Paragonix Technologies, Inc. today announces that the University of Florida Health (UF Health) is the first to enroll a pediatric heart transplant recipient into the Companys post-market registry, the Global Utilization And Registry Database for Improved preservAtion of donor HEARTs (GUARDIAN-HEART) Pediatric Registry.
  • Paragonix SherpaPak CTS is the only commercially available FDA-cleared and CE-marked medical device for heart transportation and the only device to fit small pediatric donor hearts.
  • A clinical registry dedicated to improving the preservation of the donor heart has the potential to save lives.
  • The global clinical study is registered at clinicaltrials.gov and is open to all pediatric heart transplant centers that are looking to analyze patient outcomes based on donor heart preservation methods.

Stanford Children's Health's Pediatric Transplant Program Once Again Achieves National Recognition

Retrieved on: 
Tuesday, April 6, 2021

The data is outlined in a new Pediatric Transplant Outcomes Report from Stanford Children's Health, published todaythe first day of Donate Life Month .

Key Points: 
  • The data is outlined in a new Pediatric Transplant Outcomes Report from Stanford Children's Health, published todaythe first day of Donate Life Month .
  • Over the past five years, Stanford Children's Health has performed more pediatric kidney transplants than any other U.S. program.
  • Stanford Children's Health has performed more than 800 pediatric liver and intestinal transplants since the inception of the program in 1995.
  • Patients come from across the United States and even internationally to benefit from the expertise of Stanford Children's Health's pediatric transplant program.

The National Kidney Foundation Observes National Donate Life Month in April

Retrieved on: 
Thursday, April 1, 2021

NEW YORK, April 1, 2021 /PRNewswire/ --April is National Donate Life Month and, Saturday, April 10th is National Siblings Day!

Key Points: 
  • NEW YORK, April 1, 2021 /PRNewswire/ --April is National Donate Life Month and, Saturday, April 10th is National Siblings Day!
  • The National Kidney Foundation (NKF) celebrates this important month and day by sharing critical information about living kidney donation as well as honoring National Siblings Day by highlighting inspiring stories of siblings throughout the month who have given the gift of life to a loved one.
  • "Only 1 in 5 people on the waitlist will receive a kidney transplant this year, so finding a living donor is essential to the patients' survival," said Kevin Longino, CEO of the National Kidney Foundation and a kidney transplant patient.
  • Join the conversation on social media during National Donate Life Month and National Siblings Day by using the hashtags #DonateLifeMonth and #NationalSiblingsDay.

Kidneys for Communities' new program aims to increase living kidney donations impacted by COVID

Retrieved on: 
Wednesday, March 10, 2021

Organ Procurement and Transplantation Network (OPTN), living kidney donations in 2020 dropped to just 5,237, the lowest number in just over two decades.

Key Points: 
  • Organ Procurement and Transplantation Network (OPTN), living kidney donations in 2020 dropped to just 5,237, the lowest number in just over two decades.
  • Kidneys for Communities is harnessing the power of community through proactive outreach programs that drive education and awareness about living kidney donations.
  • With this program in place, Kidneys for Communities is working to make the living kidney donor shortage a thing of the past.
  • Kidneys for Communities is unlocking the connections created through membership-based communities that can increase the number of living kidney donors in the U.S.

Annual record trend continues for deceased organ donation, deceased donor transplants

Retrieved on: 
Thursday, January 14, 2021

Organ transplants from deceased donors, totaling 33,309 in 2020, also set another annual record for the eighth consecutive year.

Key Points: 
  • Organ transplants from deceased donors, totaling 33,309 in 2020, also set another annual record for the eighth consecutive year.
  • "To again set a record for deceased donor transplants shows the amazing resilience of our organ procurement organizations and transplant hospitals.
  • A total of 5,725 living donor transplants were performed in 2020, a decrease of 22.6% over the record of 7,397 set in 2019.
  • This represents the second-highest annual total of overall transplants and is a slight decrease from the record of 39,719 set in 2019.

Paragonix Technologies Announces Enrollment Milestone for its Global Registry for Donor Heart Preservation

Retrieved on: 
Tuesday, June 2, 2020

Paragonix Technologies, Inc. today announced that its clinical global registry, the Global Utilization And Registry Database for Improved Heart Preservation (GUARDIAN) , has reached enrollment of over 100 patients that have received a donor heart.

Key Points: 
  • Paragonix Technologies, Inc. today announced that its clinical global registry, the Global Utilization And Registry Database for Improved Heart Preservation (GUARDIAN) , has reached enrollment of over 100 patients that have received a donor heart.
  • GUARDIAN , a registered clinical trial, is open to all heart transplant centers who are looking to analyze patient outcomes based on donor heart preservation methods.
  • Paragonix Technologies markets organ transportation devices that safeguard organs during the journey between donor and recipient patients.
  • Paragonix SherpaPak CTS is the only commercially available FDA cleared and CE marked transport device for heart transportation.

Donor Shield Adds Important New 7TH Donor Protection Lost Wages, Travel, & Lodging Costs Related To Complications Are Now Reimbursed

Retrieved on: 
Thursday, May 28, 2020

GREENWICH, Conn., May 28, 2020 /PRNewswire-PRWeb/ -- Today the National Kidney Registry (NKR) announced the addition of an important new 7th Donor Shield protection.

Key Points: 
  • GREENWICH, Conn., May 28, 2020 /PRNewswire-PRWeb/ -- Today the National Kidney Registry (NKR) announced the addition of an important new 7th Donor Shield protection.
  • Donors can now be reimbursed for lost wages and travel/lodging costs for any donation-related complications as part of the Donor Shield program.
  • This 7th Donor Shield protection will support those donors that require travel and/or time off work to address post-surgery complications."
  • All donors that participate in a National Kidney Registry swap, the NKR Voucher program or donate at a Direct Donor Shield center will automatically receive the Donor Shield protections.

The National Kidney Registry and Viracor Eurofins Announce Coronavirus COVID-19 Rapid Turnaround Transplant Testing for Donors and Recipients

Retrieved on: 
Monday, March 16, 2020

NKR has relied on Eurofins' specialty transplantation laboratories, VRL Eurofins and Viracor Eurofins, for over seven years to process mission critical tests to support NKR's paired exchange operation.

Key Points: 
  • NKR has relied on Eurofins' specialty transplantation laboratories, VRL Eurofins and Viracor Eurofins, for over seven years to process mission critical tests to support NKR's paired exchange operation.
  • Viracor announced availability of its COVID-19 assay on March 13th following validation in accordance with the FDA Emergency Use Authorization Guidance.
  • These test kits can be used to test living donors, recipients of living donor organs and recipients of deceased donor organs.
  • Our goal is to increase transplant safety for donors and recipients during this challenging time," said Garet Hil, Founder and CEO, National Kidney Registry.

National Kidney Registry Improves Donor Lost Wage Reimbursement Program by Eliminating Income Restrictions

Retrieved on: 
Thursday, November 21, 2019

GREENWICH, Conn., Nov. 21, 2019 /PRNewswire-PRWeb/ -- Today the National Kidney Registry (NKR) announced the elimination of all income restrictions on their Donor Shield Lost Wage Reimbursement program.

Key Points: 
  • GREENWICH, Conn., Nov. 21, 2019 /PRNewswire-PRWeb/ -- Today the National Kidney Registry (NKR) announced the elimination of all income restrictions on their Donor Shield Lost Wage Reimbursement program.
  • Additional Donor Shield protections include; travel and lodging reimbursement, coverage for uncovered complications, donation disability insurance, donation life insurance, legal support, and prioritization for a kidney should the donor need one in the future.
  • "We have been using Donor Shield for the past two years to protect every one of our living kidney donors.
  • "As a kidney donor myself, I am excited to see many top transplant centers adopting Donor Shield protections for the brave donors who step forward," said Garet Hil, Founder & CEO of the National Kidney Registry.

Hansa Biopharma: Positive Results Presented at ESOT; Imlifidase Enabled Transplantation in 46 Sensitized Patients

Retrieved on: 
Wednesday, September 18, 2019

Lena Winstedt, PhD, Head of Science at Hansa Biopharma, presented "Imlifidase For Desensitization in Sensitized Kidney Transplant Patients: Pooled Analysis of Phase 2 Trials".

Key Points: 
  • Lena Winstedt, PhD, Head of Science at Hansa Biopharma, presented "Imlifidase For Desensitization in Sensitized Kidney Transplant Patients: Pooled Analysis of Phase 2 Trials".
  • The data was based on a pooled analysis of sensitized kidney transplant patients from four single arm, 6-month, open label, Phase 2 trials of imlifidase treatment, prior to deceased and living donor transplantation in sensitized patients.
  • The analysis included 46 patients whereof 50% had a cPRA of 100%, 85% were crossmatch positive and 70% were re-transplanted.
  • Following imlifidase treatment, the DSA levels rapidly decreased and all crossmatches were converted to negative, thus enabling transplantation of all patients.